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Background: Toceranib phosphate (Palladia) has a reported objective response rate of 25% in both canine
apocrine gland anal sac adenocarcinoma (AGASACA) and thyroid carcinoma (TC), with stable disease occurring in
an additional 50-60% of dogs. The basis for the observed responses to toceranib is not known. The purpose of this
study was to evaluate AGASACA and TC samples for the expression and activation of VEGFR2, PDGFRα, PDGFRβ, KIT
and RET to assess whether dysregulation of these receptor tyrosine kinases (RTKs) may contribute to the biologic
activity of toceranib.
Results: mRNA for VEGFR2, PDGFRα/β, KIT and RET was detected in all AGASACA samples. mRNA for VEGFR2,
PDGFRα/β, and KIT was detected in all TC samples, while mRNA for RET was amplified in 10/15 samples. No
phosphorylation of VEGFR2, PDGFRα/β, or KIT was observed on the arrays. However, phosphorylation of RET was
detected in 54% of the primary AGASACA and 20% of TC. VEGFR2 was expressed in 19/24 primary and 6/10
metastatic AGASACA and 6/15 TC samples. KIT was present in 8/24 primary and 3/10 metastatic AGASACA and 9/15
TC samples. PDGFRα expression was noted in all tumor samples. In contrast PDGFRβ expression was found in only
a few tumor samples but was evident in the stroma of all tumor specimens.
Conclusions: Known targets of toceranib are expressed in both AGASAC and TC. Given the observed expression of
VEGFR and PDGFRα/β and phosphorylation of RET, these RTKs merit investigation as to their roles in the biology of
AGSACA and TC and their contribution to toceranib’s activity.
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Toceranib phosphate (PalladiaW; Pfizer Animal Health,
Madison, NJ, USA) is an oral oxindole multi-targeted re-
ceptor tyrosine kinase (RTK) inhibitor (TKI) that blocks
the activity of VEGFR2, PDGFRα,/β, FMS-like tyrosine
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reproduction in any medium, provided the orcolony stimulating factor receptor (CSFR1) [1]. It was
approved for the treatment of canine mast cell tu-
mors (MCTs) based on a single agent response rate
of approximately 43% in dogs with recurrent or non-
resectable grade 2 or 3 MCTs [2]. Toceranib also ex-
hibited activity against multiple tumor types in the original
phase 1 study, suggesting that the action of toceranib
against receptors other than KIT may play a role in the
responses observed in solid tumors [3]. In support of
this, toceranib’s kinome mirrors that of sunitinib (SutentW,
Pfizer Inc, New York, NY), a very closely related multi-
targeted TKI that has demonstrated activity against. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thyroid carcinomas, and pancreatic neuroendocrine
tumors in humans [4-6]. The biologic activity of sunitinib
in these solid tumor settings has been attributed to its
inhibition of VEGFR2, RET (another RTK) and likely
PDGFRα/β [4,5,7].
A retrospective analysis of the use of toceranib in ca-
nine solid tumors provided further support for possible
biologic activity against multiple tumor types including
apocrine gland anal sac adenocarcinoma (AGASACA),
metastatic osteosarcoma, thyroid carcinoma (TC), car-
cinomas of the head and neck, and nasal carcinoma [8].
In that study, of the 32 dogs with AGASACA that were
treated with toceranib, a partial response (PR) to therapy
as defined by RECIST criteria was noted in 8/32 (25%)
dogs and 20/32 dogs had stable disease (SD, 62.5%) for a
clinical benefit (CB) rate of 87.5%. Of the 15 dogs with
thyroid carcinoma, PR was observed in 4/15 (26.7%)
dogs and 8/15 (53.5%) experienced SD for a CB rate of
80%. These data support the notion that targets of toce-
ranib may be expressed and functional in these tumor
types.
In humans, thyroid neoplasia has been associated with
point mutations in BRAF and RAS and rearrangements
in RET and PAX8/peroxisome proliferators-activated re-
ceptor γ (PPAR γ) [9-12]. Greater than 70% of papillary
thyroid carcinomas harbor mutations in BRAF, RAS, or
RET/PTC resulting in activation of the mitogen-activated
protein kinase pathway [13] and roughly 75% of follicular
thyroid carcinomas have mutations in either RAS or PAX/
PPARγ [10]. Recognition of these mutations led to the use
of targeted therapeutics in the multimodal treatment of
thyroid tumors in people. Clinical trials evaluating multi-
targeted TKIs in the setting of progressive and/or meta-
static disease have exhibited PRs in 14-49% of patients,
with 35 to 73% of patients exhibiting SD for times excee-
ding 6 months [11,14]. The multi-targeted TKIs sunitinib,
sorafenib, motesanib and pazopanib all inhibit VEGFR2,
PDGFRα/β, and KIT and share similar response rates, yet
it remains to be elucidated inhibition of which target is
responsible for the observed biologic activity. Given the
broad range of target inhibition exhibited by these drugs,
it is possible that the clinical benefits are due to effects
exerted on multiple receptors rather than on one particu-
lar target.
In contrast to the relatively well-described molecular
profiles of human tumors, the potential targets for thera-
peutic intervention in canine cancers have not been
well-characterized.
This is particularly relevant for both AGASACA and
TC;, as there has been only one study that investigated
the expression of PDGFRβ and KIT in AGASACA [15].
The expression of other RTKs targeted by toceranib was
not examined. Another study evaluated dogs withfamilial medullary thyroid carcinoma for RET dysregula-
tion similar to that found in human familial tumors but
failed to identify any mutations in the gene after
complete sequencing [16]. Given that toceranib has bio-
logic activity against both AGASACA and TC, the pur-
pose of this study was to evaluate these tumors for the
expression of VEGFR2, PDGFRα/β, KIT and RET at both
the message and protein level to begin to dissect the
molecular basis for its observed activity.
Results
Sample demographics
Tumor samples from primary and metastatic AGASACA
were collected from a heterogenous population of dogs
that were presented to the Ohio State University Vete-
rinary Medical Center (OSU-VMC). The mean age was
9.9 years (range 7.4 to 13.9, median of 10.6 years).
Eleven of the dogs were spayed females, and 13 were
castrated males. Mixed breed dogs were overrepresented
(n = 11) with the remaining 13 dogs being defined as a
discernable breed and included Labrador retriever
(n = 4), and one dog representing each of the following
breeds: Shetland sheepdog, Siberian husky, German
shepherd dog, boxer, Lhasa apso, miniature schnauzer,
cocker spaniel, golden retriever and English setter. Ten
of the 24 dogs were hypercalcemic at the time of diagno-
sis. Nine dogs staged free of gross metastatic disease
while 15 dogs had evidence of regional lymph metastasis
at the time of diagnosis. Of the 15 dogs with lymph node
metastasis, one dog had bilateral AGASACA and one
dog also had evidence of pulmonary metastatic disease.
TC tumor samples were collected from 15 dogs that
were presented to the OSU-VMC. The mean age was
9.5 years (range 6 to 14, median of 10.0 years). Ten of
the dogs were castrated males, four were spayed females,
and one was an intact male. The most commonly repre-
sented breeds included Labrador retriever (n = 6) and
mixed breed (n = 4), with one dog representing the
following breeds: Golden retriever, pit bull terrier, bichon
frise, blue tick hound, and a Norfolk terrier. Five of the
tumors were hypersecretory, and all were diagnosed as
follicular thyroid carcinoma based on histopathology.
Two dogs had pulmonary metastasis and one dog had a
metastatic lymph node at the time of diagnosis. All 15
tumors were deemed amenable to surgical removal.
Phosphoprotein arrays
The Proteome Profiler™ Human Phospho-RTK Array
Kit provided a platform to assess phosphorylation of 42
different receptor tyrosine kinases in primary and meta-
static AGASACA tissue specimens and primary thyroid
carcinoma samples using the available flash frozen
tumor specimens. Representative examples of the RTK
arrays are shown in Figure 1 and a summary of the array
Figure 1 Phospho-RTK array profiling of canine AGASACA and TC tumors. Shown are representative examples of phosphoprotein arrays of
paired primary and metastatic AGASACA and TC using the Proteome Profiler Human Phospho-RTK Array Kit. This platform allowed simultaneous
screening of 42 different RTKs. Determination of phosphorylation was based on comparison of capture antibody of interest to positive controls
located on the periphery of the array. On these sample arrays, positive controls, EGFR, RET, ROR-1, and Tie-1 have been identified for comparison.
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in Table 1. Greater than 50% of the primary AGASACAs
demonstrated phosphorylation of EGFR (67%), Dtk/
TYRO3 (87%), Ron (54%), RET (54%) ROR1 (92%),
ROR2 (62%), while phosphorylation of FGFR3 (38%) in-
sulin-R (50%), Tie-1 (21%) and Tie-2 (25%) was observed
in a smaller percentage of samples.
All of the metastatic lymph node specimens showed
phosphorylation of ROR1 and Tie-1, with phosphoryl-
ation of EGFR (64%) also observed in a majority of the
samples. Table 2 summarizes differences in RTK phos-
phorylation between paired primary and metastatic
AGASACA samples. The TC samples demonstrated
phosphorylation of primarily EGFR (100%), Dtk/TYRO3
(53%), ROR1 (100%) and Tie-1 (100%), with insulin-RTable 1 Phosphoprotein screening results from AGASACA










EGFR 16 (67) 7 (64) 14 (100)*
Dtk/TYRO3 21 (87) 3 (27) 8 (53)
Insulin-R 12 (50) 1 (9) 6 (40)
ROR-1 22 (92) 11 (100) 15 (100)
ROR-2 15 (62) - -
Ret 13 (54) 1 (9) 3 (20)
Tie-1 5 (21) 11 (100) 15 (100)
Tie-2 6 (25) 1 (9) 6 (40)
Ron 13 (54) 1 (9) 5 (30)
FGFR3 9 (38) 1 (9) -(40%), and RET (20%), Tie-2 (40%) and Ron (30%) oc-
curring less frequently.Reverse transcriptase -polyermase chain reaction
While the phosphorylation array represents a useful
screening tool to assess tissue samples for activation of
key RTKs, it does not detect total protein, and will
therefore not give a complete picture as to the extent of
tumor RTK expression. To provide an initial assessment
of expression of the RTKs, total RNA was extracted
from normal anal sac and thyroid glands, primary and
metastatic AGASACA and primary TC tissue samples,
and RT-PCR was performed for canine VEGFR2, KIT,
RET, PDGFRα and PDGFRβ. Message for all of these
RTKs was detected in all AGASACA tissue samples and
paired metastatic lymph nodes. Interestingly, message






EGFR 5 (45) 7 (64)
Dtk/TYRO3 10 (91) 3 (27)
Insulin-R 4 (36) 1 (9)
ROR-1 11 (100) 11 (100)
Ret 5 (45) 1 (9)
Tie-1 1 (9) 11 (100)
Tie-2 1 (9) 1 (9)
Ron 7 (64) 1 (9)
FGFR3 4 (63) 1 (9)
Table 4 RTK expression in metastatic AGASACA samples
by IHC
RTK Negative + ++ +++ Predominant
localization
VEGFR2 4 (40) 1 (10) 0 5 (50) C
PDGFRα 0 0 0 10 (100) N, C
PDGFRβ 9 (90) 1 (10) 0 0 M
Kit 7 (70) 0 2 (20) 1 (10) C
C: cytoplasmic; M: membranous; N: nuclear.
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PDGFR-α and PDGFR-β was detected in all TC samples,
while message for RET was detected in only 10/15
tumors. Normal thyroid tissue samples expressed mes-
sage for all of the RTKs.
Immunohistochemistry
Core samples from all tumor tissues except one metastatic
AGASACA lymph node were available for evaluation, and
tissue microarrays were constructed to evaluate expression
of receptors of interest in all samples (Tables 3,4,5,6 and
Figure 2). Positive immunoreactivity for VEGFR2 was
noted in the cytoplasm of tumor cells in 19/24 primary
and 6/10 metastatic AGASACA and 6/15 TC samples.
Positive immunoreactivity for KIT in the cytoplasm of
tumor cells was noted in 8/24 primary and 3/10 metastatic
AGASACA and 9/15 TC samples. Strong cytoplasmic and
stromal staining for PDGFRα was noted in all primary and
metastatic AGASACA and all of the TC samples. Cyto-
plasmic PDGFRβ expression was noted in 4/24 primary
and 1/10 metastatic AGASACA and 4/15 TC tumor cells,
while intense stromal staining was noted in all tumor sam-
ples. The normal anal sac samples exhibited positive
immunoreactivity for VEGFR2 and PDGFRα while normal
thyroid samples displayed positive reactivity for VEGFR2,
PDGFRα and KIT. Unfortunately, RET expression could
not be evaluated on this platform due to the lack of a vali-
dated antibody for use in canine formalin-fixed paraffin
embedded samples.
Discussion
The purpose of this study was to evaluate AGASACA
and TC for the expression of VEGFR2, PDGFRα/β, Kit
and Ret at both the message and protein level to begin
to dissect the molecular basis for the observed response
of these tumors to toceranib. While the messages for
VEGFR2, Kit, PDGFRα and PDGFRβ were detected in
all tumor samples, only PDGFR-α and VEGFR2 expres-
sion were detected in all AGASACA and TC tumor cells
by IHC. Strong expression of PDGFRβ was observed in
the stroma of both tumor sets. While message for RET
was identified in all tumor samples, this RTK was found
to be phosphorylated in only 54% of AGASACA and
20% of TC samples. Similarly, VEGFR2, PDGFRα andTable 3 RTK expression in primary AGASACA samples by
IHC
RTK Negative + ++ +++ Predominant
localization
VEGFR2 4 (17) 6 (25) 2 (8) 11 (46) C
PDGFRα 0 0 0 24 (100) N, C
PDGFRβ 20 (83) 3 (13) 1 (4) 0 M
Kit 16 (67) 3 (13) 2 (8) 3 (13) C
C: cytoplasmic; M: membranous; N: nuclear.PDGFRβ were detected in all tumor specimens by IHC;
however,phosphorylation of these was not observed on
the arrays. These data suggest that while these RTKs
may be present in most AGASACAs and TCs, most
probably they do not exist in a state of continual activa-
tion/signaling observed in the setting of typical RTK
dysregulation associated with mutation, chromosomal
translocation, and over-expression. As such, the majority
of SD/CB in dogs with AGASACA and TC may relate to
inhibition of RTKs that are in support of tumor growth
(i.e., VEGFR2 and PDGFRβ associated with vascular
endothelium and stroma) rather than a direct inhibition
of specific RTKs expressed on tumor cells.
To date, no driver mutations or chromosomal altera-
tions have been reported in either canine AGASACA or
TC. A report of a canine pedigree with familial medul-
lary TC (MTC) that clinically paralleled MTC in humans
failed to demonstrate a mutation in RET [16]. Another
study identified the presence of somatic mutations in
p53 in canine TC [17]. Aside from the well documented
relationship between AGASACA and parathyroid hor-
mone related- protein, limited data exists regarding the
genetics and molecular biology of this tumor [18-20].
With regard to AGASACA, a higher frequency of the
disease has been documented in English Cocker Spaniels
with the DLA-DQB1 allele [21], and a direct relationship
between E-cadherin expression assessed by IHC on for-
malin fixed samples and survival in dogs with AGA-
SACA has been documented [22]. As previously
mentioned, a previous study of 77 archival AGASACA
samples found 19.5% expressed positive immunoreactiv-
ity for PDGFRβ and 2.6% expressed positive immunor-
eactivity for KIT [15]. Clearly, more detailed
investigations of the molecular aberrations in bothTable 5 RTK expression in TC samples by IHC
RTK Negative + ++ +++ Predominant
localization
VEGFR2 13 (87) 1 (7) 0 1 (7) C
PDGFRα 0 0 0 15 (100) C
PDGFRβ 11 (73) 1 (7) 2 (13) 1 (7) C
Kit 6 (40) 1 (7) 4 (270 4 (27) C
C: cytoplasmic; M: membranous; N: nuclear.











VEGFR2 0 1 (10) 0
PDGFRα 24 (100) 10 (100) 15 (100)
PDGFRβ 24 (100) 10 (100) 15 (100)
Kit 0 0 0
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the key biological drivers of these diseases.
In contrast to the lack of published data in veterinary
medicine, significant strides have been made in under-
standing the molecular biology of differentiated thyroid
cancer (DTC) in people, with specific gene signatures
and tumor-initiating events having been identified [23].
DTC includes papillary TC (PTC), follicular TC (FTC),
and Hurthle cell carcinoma (HCC). Although often
grouped together, there are molecular differences amongFigure 2 Immunohistochemistry for VEGFR2, KIT, and PDGFR α/β. The
probed for VEGFR2, KIT, PDGFRα, and PDGFRβ. Positive immunoreactivity w
representative images for primary and metastatic AGASACA and TC for eacPTC, FTC and HCC that are associated with phenotype
and biological behavior. For example, alterations in sev-
eral RTKs have been identified, with the best described
being dysregulation of RET present in 5-30% of sporadic
PTC in adults [24,25]. Chromosomal rearrangements
and mutations resulting in ligand-independent constitu-
tive activation of RET induce neoplastic transformation
of thyroid follicular cells through the activation of mul-
tiple intracellular signal transduction pathways [26].
Dysregulation of NTRK1, BRAF, Ras, and PAX/PPARγ
has also been associated with the development and pro-
gression of other thyroid cancers [24,27].
In the present study, message for RET was detected in
the majority of samples and evidence of phosphorylated
protein was detected in 20% of TC and 54% of primary
AGASACA. In the paired primary and metastatic AGA-
SACA samples, 5 of the primary tumors had evidence of
phosphorylated RET as detected by the phospho-RTK
arrays, while it was only detected in one of the lymph
nodes suggesting down-regulation of the protein or lossTMA constructed for primary and metastatic AGASACA and TC were
as scored and location of staining was noted. Shown are
h RTK evaluated.
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an antibody for probing of canine RET for IHC has yet
to be validated and limited the authors’ ability to assess
protein expression on the TMA.
Activating mutations in RET have been documented
in human PTC and MTC, multiple endocrine neoplasia
2 syndromes, pheochromocytoma, and paragangliomas
that are known to drive tumor cell growth [28] [29].
There is also evidence accumulating to support RET ac-
tivation and signaling in the pathogenesis of a subset of
estrogen receptor α positive breast cancer [30] and over-
expression of RET has been reported in prostate, pancre-
atic, neural crest derived tumors, bile duct carcinomas,
melanoma, and lung cancers [31-37]. VEGFR and RET
exhibit structural similarity and as such, TKIs that target
VEGFR such as sunitinib, motesanib and vandetanib
have been demonstrated to also inhibit RET phosphoryl-
ation [5,27]. Sunitinib, a TKI with an inhibitory profile
very similar to that of toceranib, has been used as ther-
apy for progressive/metastatic DTC in people resulting
in modest objective responses but promising CB with
prolonged periods of disease stabilization [5,14,27] A re-
cent kinome analysis of toceranib demonstrated that
RET is a target of this TKI (London et al, unpublished)
suggesting that as is the case with several human carcin-
omas, phosphorylation of RET in AGASACA and TC
from some dogs may be driving cell growth and survival
and could therefore be responsible for the objective re-
sponse to therapy noted in a subset of dogs on
toceranib.
The role of PDGFR in thyroid cancer pathogenesis has
also been investigated [38]. In one study, 8 patients with
advanced DTC exhibiting overexpression of PDGF recep-
tors based on IHC were treated with imatinib, a TKI that
targets Bcr-Abl, PDGFR and KIT [38]. Partial responses
were documented in 2/8 with another 4/8 experiencing
SD for a CB of 75% suggesting that PDGFR may represent
a target for therapeutic intervention. In the current study,
we found PDGFRα to be expressed in all tumor cells of all
canine TC samples, while PDGFRβ was primarily
expressed in the tumor stroma by IHC. Interestingly,
phosphorylation of these receptors was not documented
using the phospho-RTK array, indicating that while
expressed, PDGFRα/β is likely not driving tumor growth
and survival through constitutive activation.
Similar to the case of TC, we identified expression of
PGDFRα in the tumor cells of all AGASACA samples
and PDGFRβ in the tumor stroma by IHC. Expression of
PDGFRβ in tumor cells was restricted to only 16% of
tumor samples, which is consistent with a previous study
that found 15 of 77 samples to be positive for this recep-
tor [15]. The association of PDGFRβ primarily with the
stroma, and not tumor cells, in both AGASACA and TC
suggests that toceranib may be exerting much of itsbiologic activity through effects on the tumor stroma
and blood supply, particularly in cases where SD is
observed.
In our study, message for KIT was detected in all pri-
mary and metastatic AGASACA, as well as TC tumor
samples. In contrast, KIT protein immunoreactivity as
assessed by IHC was found in only 8/24 primary and 3/
10 LN AGASACA samples and 9/15 of the TC samples,
with expression being localized to tumor cells, not
stroma. The discordant results between message and
protein expression may be secondary to detection of
KIT message present in mast cells and other inflamma-
tory cells present within the tumor. Our results also dif-
fer from a previous study in which only 2/77 AGASACA
samples were positive for KIT by IHC. The reason for
this discordance is unclear, although differences in tissue
processing, primary antibody used and staining protocol
may be contributory. Nevertheless, phosphorylation of
KIT was not detected on the phospho-RTK arrays sug-
gesting that as with PDGFRβ, KIT signaling is probably
not playing a role in the driving tumor cell growth and
proliferation of AGASACA and TC in dogs. This is con-
sistent with the biology of thyroid neoplasia in people in
which KIT dysregulation is not believed to be a con-
tributory factor in tumor biology.
Message for VEGFR2 was detected in tumor cells from
all AGASACA and TC samples evaluated. While most
(19/25 primary and 6/10 LN metastases) expressed
VEGFR2 protein as assessed by IHC, only 2/15 TC sam-
ples were positive for protein. As with PDGFR and KIT,
there was no evidence of VEGFR2 phosphorylation on
the phospho-RTK arrays. While stromal VEGFR2 ex-
pression was only noted in one AGASACA LN sample,
this may be due to the fact that VEGFR2 is primarily
expressed on circulating endothelial precursors and neo-
vessels, rather than mature blood vessels, and as such it
may be difficult to identify these populations in the for-
malin-fixed specimens. However, the role of VEGFR2
and angiogenesis in TC is supported by several observa-
tions including the high degree of vascularity of thyroid
tumors, the correlation between increased VEGF expres-
sion and development of metastatic disease, and evi-
dence revealing that VEGFR2 inhibition may contribute
biologic responses observed with multi-targeted RTK in-
hibitor therapy in humans [39].
The phospho-RTK arrays identified evidence of phos-
phorylation of several other RTKs that may be influen-
tial in the development and progression of both
AGASACA and TC. Tie-1 and Tie-2 comprise the Tie
family of RTKs and share the angiopoietins as activat-
ing ligands. Tie-1 is typically expressed on vascular
endothelium and has been implicated in tumor angio-
genesis [40]. Expression of Tie-1 has been reported in
breast, gastric, colon, and thyroid cancers, but
Table 7 RT-PCR primer sets for canine RTKs
RTK Primers Product size (bp
c-Kit 232 F: 5’ – GAG AAC ACA CAC AAC GAA TG – 3’
414R: 5’ – GCA GCG GAC CAG CGT ATC ATT G – 3’
185
PDGFRα 1917 F: 5’ – GCT CTC ATG TCG GAA CTG AAG – 3’
2152R: 5’ – GTG TGC TGT CAT CAG CAG G – 3’
237
PDGFRβ 2235 F: 5’ – GAC GAG TCA GTG GAT TAC GTG – 3’
2562R: 5’ – GTC TCT CAT GAT GTC ACG AGC CAG – 3’
329
c-Ret 206 F: 5’ – GCC ACT GTG ATG CTG TAG AGA GCA G – 3’
259R: 5’ – GTG CGG CAG AGC TCA TCA CAC AGT GG – 3’
210
VEGFR2 1537 F: 5’ – GTA AGT ACC CTT GTT ATC CAA GCA GCC – 3’
1728R: 5’ – CGT AGT TCT GTC TGC AGT GCA CCA C – 3’
195
GAPDH 526 F: 5’ – GTC CAT GCC ATC ACT GCC ACC CAG – 3’
718R: 5’ – CTG ATA CAT TGG GGG TGG GGA CAC – 3’
196
Urie et al. BMC Veterinary Research 2012, 8:67 Page 7 of 9
http://www.biomedcentral.com/1746-6148/8/67constitutive activation has only been proven in a breast
cancer cell line [40,41]. In a study of 135 patients with
TC, Tie-1 immunoreactivity was observed in PTC and
anaplastic TC but not FTC or follicular adenomas, and
it was also noted that large tumors had decreased ex-
pression [41]. Based on the recognized biological dif-
ferences between PTC and FTC, the difference in Tie-
1 expression may influence the lymph node metastases
that are commonly observed in PTC [41]. Tie-2 ex-
pression has been shown to be increased with breast
cancer and is also expressed in human PTC, FTC and
follicular adenomas [42,43]. A correlation has been
demonstrated between Tie-2 expression and increased
risk of metastasis and relapse in breast cancer patients,
and expression is associated with decreased survival
[42]. Although the role of Tie-2 in thyroid cancer has
not been clearly delineated, it is thought to be asso-
ciated with cellular proliferation [43]. While the roles
of both Tie-1 and Tie-2 in AGASACA and TC are
currently unknown, further investigation is warranted
given the observed phosphorylation of both receptors
in many tumor samples in this study.
It is well recognized that EGFR dysregulation is a
powerful oncogenic driver with overexpression and acti-
vating mutations documented in numerous tumors of
epithelial origin [44]. While expression of EGFR has
been evaluated in canine mammary tumors, brain
tumors, nasal carcinomas, and lung tumors, it has yet to
be proven as a driver of tumor proliferation in any ca-
nine cancer [45]. A recent report evaluating several mar-
kers in human thyroid carcinoma found strong EGFR
expression in invasive PTC and FTC [46]. Vandetanib, a
TKI that inhibits EGFR as well as VEGFR and RET, is
approved for the treatment of advanced MTC but the
impact of EGFR inhibition in this disease is unknown
and to date, there is limited data about its activity in the
treatment of DTC, although clinical trials are presently
underway [5,27]. EGFR expression was not evaluated in)the present study, but evidence of phosphorylation sup-
ports further investigation.Conclusions
The descriptive nature of this project has inherent limi-
tations. Protein expression by IHC does not directly
correlate with a causative role in tumor growth and
survival, and while phosphorylation of several key RTKs
was observed on the arrays, their exact contribution to
AGASAC and TC was not investigated. The tumor
samples in this study were not microdissected, and thus
included both tumor and stroma in protein lysates and
RNA as well as non-neoplastic cell infiltrates such as
mast cells or residual lymph node. Nevertheless, the
findings of VEGFR and PDGFR protein expression and
phosphorylation of RET merit further investigation as
to their roles in the biology of AGSACA and TC as
well as to their contribution to the observed response
to toceranib.Methods
Tissue samples
Tumor tissue samples were collected from clinical cases
that presented to the OSU-VMC. Consent for tissue col-
lection was obtained from all owners in accordance with
an approved IACUC protocol (2010A0015) and collected
by the OSU-VMC Biospecimen Repository. A total of 24
primary AGASACA with 11 paired metastatic regional
lymph nodes and 15 primary TC were identified. Surgi-
cal and post-mortem collected tumor samples were snap
frozen in liquid nitrogen and stored at −80°C. Tissue
samples were also placed in formalin and processed for
routine paraffin embedding for histopathology. The
medical records of all dogs were reviewed and data per-
taining to signalment, staging, treatment, and survival
were abstracted.
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To assess relative phosphorylation of 42 different RTKs
in primary tumor samples, the Proteome ProfilerTM ™
Human Phospho-RTK Array Kit was used (R&D Sys-
tems, Minneapolis, MN, USA). Briefly, frozen tumor
samples were pulverized using a frozen mortar and pes-
tle. The resulting powder was resuspended in liquid ni-
trogen, and transferred to 1.5 mL microcentrifuge tube.
Once the liquid nitrogen evaporated away, the samples
were allowed to thaw on ice and resuspended in tissue
lysis buffer containing 20 mM Tris–HCl, 2 mM EDTA,
137 mM NaCl, 10 μg/mL aprotinin, 10 μg/mL leupeptin,
1 mM sodium orthovanadate, 1% IGEPALW CA 630, and
10% glycerol. Samples were rocked for 1 hour at 4°C,
centrifuged for 15 minutes at 14,000 RPM at 4°C, and
supernatants collected. Bradford protein quantification
assay was performed on the extracts using BioRad Re-
agent (BioRad, Hercules, CA, USA). 100 μg of protein
lysate was used to perform the RTK array following the
manufacturer’s instructions.
RNA isolation and RT-PCR
Powdered sample of homogenized tissue (described
above) was placed in 500uL of TRIzol (Invitrogen Cor-
poration, Carlsbad, CA) and stored at −80°C until RNA
isolation according to the manufacturer’s protocol. RNA
was quanitated with the Nanodrop-100 spectrophotom-
eter (Thermo Scientific, Wilmington, DE, USA). Super-
ScriptIII (Invitrogen Corporation, Carlsbad, CA) reverse
transcriptase was used for reverse transcription as previ-
ously described [47]. For the PCR reactions, primers
directed against canine genes of interest (Table 7) were
designed to span an intron and were used to amplify
product from the cDNA. The program for each PCR re-
action was unique for each primer set and was designed
to generate a single PCR product. Taq polyermase (Pro-
mega, Madison, WI) was used for each reaction. The
amplified PCR products were separated by agarose gel
electrophoresis, stained with ethidium bromide and
visualized with ultraviolet light. All PCR products were
verified by sequencing at The OSU Shared Resources
Nucleic Acid Core Laboratory.
Tissue microarray construction and
immunohistochemistry
Representative areas of tumor tissue were identified on
hematoxylin-eosin (HE) stained sections by a single
pathologist (DR) for triplicate core sampling. Cores were
extracted from the corresponding areas of paraffin em-
bedded blocks and inserted into predetermined sites on
the TMA recipient block. Immunohistochemical staining
was performed for VEGFR2 (Santa Cruz Biotechnology;
1:10 dilution) [48], PDGFRα (Santa Cruz Biotechnology;
1:50) [49], PDGFRβ (Biogenex Labs; 1:200) [15], andKIT (Dako; 1:400), on all ASACA and TC samples.
Negative controls consisted of irrelevant isotype
matched antibody at matched dilutions. Both the con-
struction of the TMA bloc and immunohistochemical
staining were performed by the OSU- CVM Veterinary
Biosciences Histopathology Laboratory.
Scoring of immunoreactivity
Subjective quantitative scoring of positive or negative
immunoreactivity of cells and stroma within the cores
were performed by three of the investigators (WK, DR,
BU). Percentage of neoplastic cells staining positive
was scored as follows: <5%=0, 5-25%= 1, 26-50%= 2,
and >50% =3. Location of staining was also noted as
cytoplasmic (C), membranous (M), nuclear (N), and stro-
mal (S).
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